Galera Therapeutics Inc [GRTX] Revenue clocked in at $0.00 million, down -93.48% YTD: What’s Next?

- Advertisements -

Galera Therapeutics Inc [NASDAQ: GRTX] plunged by -$0.11 during the normal trading session on Tuesday and reaching a high of $0.1069 during the day while it closed the day at $0.10. The company report on October 31, 2023 at 7:00 AM that Galera Announces Receipt of Type A Meeting Minutes and Strategic Update.

FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM).

- Advertisements -

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials.

Galera Therapeutics Inc stock has also loss -46.06% of its value over the past 7 days. However, GRTX stock has declined by -95.46% in the 3 months of the year. Over the past six months meanwhile, it has lost -96.91% and lost -93.48% year-on date.

- Advertisements -

The market cap for GRTX stock reached $4.27 million, with 43.93 million shares outstanding and 35.92 million shares in the current float. Compared to the average trading volume of 4.99M shares, GRTX reached a trading volume of 24615719 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Galera Therapeutics Inc [GRTX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GRTX shares is $0.35 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GRTX stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Piper Sandler have made an estimate for Galera Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 10, 2023.

- Advertisements -

GRTX stock trade performance evaluation

Galera Therapeutics Inc [GRTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -46.06. With this latest performance, GRTX shares dropped by -44.13% in over the last four-week period, additionally sinking by -96.91% over the last 6 months – not to mention a drop of -94.12% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GRTX stock in for the last two-week period is set at 30.18, with the RSI for the last a single of trading hit 27.85, and the three-weeks RSI is set at 29.12 for Galera Therapeutics Inc [GRTX]. The present Moving Average for the last 50 days of trading for this stock 0.1962, while it was recorded at 0.1882 for the last single week of trading, and 1.8954 for the last 200 days.

Galera Therapeutics Inc [GRTX]: An insightful look at the core fundamentals

Return on Total Capital for GRTX is now -101.58, given the latest momentum, and Return on Invested Capital for the company is -123.75. Additionally, GRTX Total Debt to Total Capital is recorded at 457.99, with Total Debt to Total Assets ending up at 317.19.

Reflecting on the efficiency of the workforce at the company, Galera Therapeutics Inc [GRTX] managed to generate an average of -$2,007,161 per employee.Galera Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.08 and a Current Ratio set at 3.08.

Earnings per share (EPS) analysis for Galera Therapeutics Inc [GRTX] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GRTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Galera Therapeutics Inc go to 34.40%.

Galera Therapeutics Inc [GRTX]: Institutional Ownership

The top three institutional holders of GRTX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in GRTX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in GRTX stock with ownership which is approximately 5.7994%.

- Advertisements -

Leave a Reply

Your email address will not be published. Required fields are marked *